Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Clinical Trials
Return to: PBR Home | Contract Research & Services | Clinical Trials

Clinical Trials

AstraZeneca elects to return AZD9412 drug rights to Synairgen By PBR Staff Writer
AstraZeneca has opted to return rights on drug AZD9412 (inhaled interferon beta) to Synairgen, which did not meet the pharma giant's predefined criteria for progression in a trial.
Contract Research & Services > Clinical Trials > News
Clinical trial technology firm Science 37 raises $29m funding Science 37 has raised $29m in Series C funding, led by Glynn Capital Management with participation from GV, to bring clinical trials directly into patients’ homes.
Contract Research & Services > Clinical Trials > News Pfizer's Zavicefta matches standard-of-care in treating hospital-acquired pneumonia in phase 3 study Results from the phase 3 REPROVE study assessing Pfizer's fixed-dose antibacterial combo Zavicefta (ceftazidime-avibactam) in patients with hospital-acquired pneumonia (HAP) demonstrated a comparable cure rate to carbapenem antibiotic therapy, considered the standard of care.
Contract Research & Services > Clinical Trials > News
See more Clinical Trials news

Latest Clinical Trials News and Insight

View all Clinical Trials news or find news targeted to your interests
NGM Bio’s NGM282 succeeds in nonalcoholic steatohepatitis phase 2 trial
NGM Bio’s NGM282 has met the primary and key secondary endpoints in a Phase 2 trial in nonalcoholic steatohepatitis (NASH) patients.
Contract Research & Services > Clinical Trials > News
AbbVie's pan-genotypic HCV regimen achieves 99% cure rate in phase 3 study
By PBR Staff Writer
A phase 3 study demonstrated that AbbVie's pan-genotypic ribavirin-free HCV regimen of glecaprevir/pibrentasvir (G/P) achieved a 99% cure rate after 12 weeks of treatment.
Contract Research & Services > Clinical Trials > News
Ultragenyx's hypophosphatemia drug succeeds in phase 3 study
Ultragenyx Pharmaceutical, Kyowa Hakko Kirin and Kyowa Kirin International have reported positive 24-week data from the randomized, double-blind, placebo-controlled Phase 3 trial of burosumab (KRN23) in X-linked hypophosphatemia (XLH) adult patients.
Contract Research & Services > Clinical Trials > News
Relypsa’s Veltassa shows consistent efficacy in phase 4 trial to treat hyperkalemia
By PKBR Staff Writer
Relypsa’s Veltassa (patiromer) has demonstrated consistent effficacy and safety in phase 4 Tourmaline study in patients with hyperkalemia.
Contract Research & Services > Clinical Trials > News
Mateon’s phase 2/3 trial in platinum-resistant ovarian cancer yields positive results
Mateon Therapeutics has revealed encouraging data from its first interim scheduled analysis of the ongoing phase 2/3 trial (FOCUS) in platinum resistant ovarian cancer (prOC) patients.
Contract Research & Services > Clinical Trials > News
OncoMed’s small cell lung cancer drug tarextumab fails in phase 2 trial
By PBR Staff Writer
A phase 2 study of OncoMed Pharmaceuticals' tarextumab in small cell lung cancer has failed to meet its primary and secondary endpoints.
Contract Research & Services > Clinical Trials > News
Roche's emicizumab reduces bleeds in children with hemophilia A
By PBR Staff Writer
Interim data from the phase 3 HAVEN 2 study evaluating Roche's emicizumab for reducing bleeding episodes in children younger than 12 years of age with hemophilia A demonstrated a clinically meaningful treatment effect.
Contract Research & Services > Clinical Trials > News
Novan’s topical anti-fungal treatment SB208 succeeds in phase 2 trial
By PBR Staff Writer
A phase 2 trial has revealed that Novan’s topical and silicone based-gel, SB208, demonstrated a significant effect in the treatment of infections caused by dermatophytes such as Trichophyton rubrum (T. rubrum).
Contract Research & Services > Clinical Trials > News
OncoMed's demcizumab fails to meet primary endpoint in pancreatic cancer trial
OncoMed Pharmaceuticals’ demcizumab (anti-DLL4, OMP-21M18) has failed to meet its primary endpoint in the Phase 2 YOSEMITE clinical trial in combination with Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin bound) plus gemcitabine in previously untreated metastatic pancreatic cancer patients.
Contract Research & Services > Clinical Trials > News
Roche’s Alecensa shows significant effect over Pfizer’s Xalkori to treat ALK- positive NSCLC
By PBR Staff Writer
A phase III study has revealed that Roche’s Alecensa (alectinib) showed significant effect over Pfizer’s Xalkori (crizotinib) in the treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Contract Research & Services > Clinical Trials > News
View all Clinical Trials news or find news targeted to your interests